| 0.9 0.137 (17.89%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.1  |
1-year : | 1.29 |
| Resists | First : | 0.94 |
Second : | 1.1 |
| Pivot price | 0.6 |
|||
| Supports | First : | 0.63 |
Second : | 0.43 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.58 |
| MA(100) : | 0.54 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.9 |
D(3) : | 86.2 |
| RSI | RSI(14): 84.7 |
|||
| 52-week | High : | 1.18 | Low : | 0.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IPSC ] has closed above the upper band by 23.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 258.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.95 | 0.95 - 0.96 |
| Low: | 0.72 - 0.73 | 0.73 - 0.73 |
| Close: | 0.89 - 0.9 | 0.9 - 0.9 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Wed, 17 Dec 2025
There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st
Tue, 16 Dec 2025
Brent Pfeiffenberger Purchases 52,000 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Fri, 12 Dec 2025
Century Therapeutics, Inc. Updates on Cell Therapy Developments - TradingView — Track All Markets
Tue, 09 Dec 2025
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors - Nasdaq
Tue, 09 Dec 2025
Century Therapeutics Appoints Accomplished Biotechnology - GlobeNewswire
Tue, 25 Nov 2025
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 87 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 26 (%) |
| Held by Institutions | 38.5 (%) |
| Shares Short | 608 (K) |
| Shares Short P.Month | 350 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.03 |
| Profit Margin | -23.4 % |
| Operating Margin | -20 % |
| Return on Assets (ttm) | -4.5 % |
| Return on Equity (ttm) | -14.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.09 |
| Sales Per Share | 1.29 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -112 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -2.82 |
| PEG Ratio | 0 |
| Price to Book value | 0.44 |
| Price to Sales | 0.69 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|